KRAS 測試的全球市場 - 市場規模（依細分市場）、佔有率、監管、償付、預測（~2033年）

本報告研究和分析了全球 KRAS 測試市場，提供了有關主要參與者、市場佔有率、主要趨勢、創新產品和技術以及競爭格局的資訊。

市場模型的主要內容如下。

已上市的 KRAS 測試和不斷變化的競爭格局

• 對主要產業趨勢的考察
• KRAS 檢測市場年收入與市場前景（依細分市場）（2015-2033年）
• 有關單位數量、平均售價和市場價值的市場級資料

全球、區域和國家層面的特定市場考察

• 依地區細分全球趨勢的特定市場定性資訊和國家考察
• KRAS檢測市場的SWOT分析
• KRAS 測試市場競爭動態的考察與趨勢

掌握包括醫療保健系統概述真實情況，促進市場了解。市場進入部分還提供有關償付政策和監管環境的訊息，能夠更深入地研究市場動態。

• 各國醫療保健系統概覽
• 依國家/地區劃分的償付政策
• 各國醫療科技監理狀況

目標公司

• Roche Diagnostics International Ltd + Foundation Medicine Inc
• Qiagen NV
• Agilent Technologies Inc
• Illumina Inc
• Thermo Fisher Scientific Inc
• Abbott Laboratories
• NimaGen BV
• Agena Bioscience Inc
• New England Biolabs Inc
• Amoy Diagnostics Co Ltd
• HLB PanaGene Co Ltd
• EntroGen, Inc
• Sysmex Inostics GmbH
• Biocartis Group NV
• 其他

KRAS Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Kirsten Rat Sarcoma (KRAS) is a downstream signaling molecule in the EGFR cellular pathway with roles in cell growth and proliferation.KRAS gene tests are carried out to detect gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including colorectal cancer, certain lung cancers and some leukemias.

There are no clinically approved therapies that target KRAS. However, its mutational status serves as an indication for response to approved anti-EGFR receptor antibodies in CRC and Tyrosine Kinase Inhibitors (TKIs) in NSCLC.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed KRAS Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total KRAS Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for KRAS Tests market.
• Competitive dynamics insights and trends provided for KRAS Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Roche Diagnostics International Ltd + Foundation Medicine Inc, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Agena Bioscience Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, EntroGen, Inc, Sysmex Inostics GmbH, Biocartis Group NV, and others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the KRAS Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving KRAS Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the KRAS Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific KRAS Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.